세계의 칼시토닌 유전자 관련 펩타이드 수용체 길항제 시장 보고서(2025년)

Calcitonin gene-related peptide (CGRP) receptor antagonists are a class of medications designed to block the effects of CGRP, a molecule that plays a key role in transmitting pain signals and dilating blood vessels in order to prevent or treat migraines and cluster headaches. These drugs offer targeted relief from migraines and generally result in fewer side effects than traditional migraine treatments, thereby enhancing patient outcomes and overall quality of life.

The primary categories of CGRP receptor antagonists include small molecule antagonists, monoclonal antibodies, and peptide-based antagonists. Small molecule antagonists are low-molecular-weight compounds that inhibit specific proteins like the CGRP receptor, aiding in the prevention or reduction of migraine symptoms. Common drugs in this class include zavegepant, ubrogepant, olcegepant, telcegepant, rimegepant, and others. These medications are used across various applications, such as migraine treatment, pain management, cardiovascular conditions, and bone disorders, and are utilized by end users including hospitals, clinics, homecare settings, and pharmaceutical companies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The calcitonin gene-related peptide receptor antagonist market research report is one of a series of new reports from The Business Research Company that provides calcitonin gene-related peptide receptor antagonist market statistics, including calcitonin gene-related peptide receptor antagonist industry global market size, regional shares, competitors with a calcitonin gene-related peptide receptor antagonist market share, calcitonin gene-related peptide receptor antagonist market segments, market trends and opportunities, and any further data you may need to thrive in the calcitonin gene-related peptide receptor antagonist industry. This calcitonin gene-related peptide receptor antagonist market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The calcitonin gene-related peptide receptor antagonist market size has grown rapidly in recent years. It will grow from $2.06 billion in 2024 to $2.30 billion in 2025 at a compound annual growth rate (CAGR) of 11.2%. Growth during the historic period can be attributed to the expansion of clinical trials validating the efficacy of CGRP antagonists, increased global healthcare spending, higher diagnosis rates of migraine disorders, greater adoption of preventive migraine therapies, and a robust development pipeline of CGRP antagonist compounds.

The calcitonin gene-related peptide receptor antagonist market size is expected to see rapid growth in the next few years. It will grow to $3.48 billion in 2029 at a compound annual growth rate (CAGR) of 11.0%. Growth in the forecast period can be attributed to favorable regulatory approvals, increased research funding, rising adoption of innovative migraine prevention therapies, and a growing geriatric population. Key trends expected during this period include the development of oral small molecule therapies, wearable-triggered dosing devices, long-acting injectable formulations, nanoparticle-based drug delivery systems, and ongoing investigations into gene therapy approaches.

The rising prevalence of migraines is expected to drive the growth of the calcitonin gene-related peptide receptor antagonist market in the coming years. Migraines are severe headaches characterized by throbbing pain, often localized to one side of the head. The increase in migraine cases is attributed to heightened stress from hectic urban lifestyles, irregular sleep patterns, and greater exposure to noise, pollution, and bright lights as more people relocate to cities. Calcitonin gene-related peptide receptor antagonists work by blocking CGRP, a protein that causes blood vessels to widen and transmits pain signals during migraine attacks, thereby alleviating headache pain and related symptoms. For example, a report published by the National Library of Medicine in April 2024 noted that about 61,204 individuals in the US were diagnosed with migraines by a physician in 2022, marking a 5.5% increase from 2021. This growing incidence of migraines is fueling the market expansion for CGRP receptor antagonists.

Leading companies in the calcitonin gene-related peptide receptor antagonist market are emphasizing the approval of innovative therapies, including oral CGRP receptor antagonists, which aim to improve the effectiveness of migraine treatments, broaden therapeutic uses, and offer more convenient dosing options. Oral CGRP receptor antagonists are small-molecule drugs that block CGRP, a protein associated with migraine episodes, and help in migraine prevention. For instance, in April 2023, AbbVie Inc., a US biotechnology firm, received approval from the U.S. Food and Drug Administration (FDA) for QULIPTA (atogepant) to treat chronic migraine in adults. QULIPTA is an oral, once-daily CGRP receptor antagonist designed for the preventive treatment of migraines in adults, approved for both episodic and chronic migraines in the United States. It functions by inhibiting CGRP, a protein elevated during migraine attacks that contributes to pain signaling and brain inflammation. QULIPTA is available in tablet strengths of 10 mg, 30 mg, and 60 mg, with the 60 mg dosage specifically evaluated for chronic migraine prevention.

In October 2022, Pfizer Inc., a US pharmaceutical company, acquired Biohaven Pharmaceutical Holding Company Ltd. for an undisclosed amount. Through this acquisition, Pfizer intends to enhance its migraine treatment portfolio and support long-term growth by combining Biohaven's innovative therapies with Pfizer's global distribution capabilities to better serve patients worldwide. Biohaven Pharmaceutical Holding Company Ltd. is a US biopharmaceutical company specializing in calcitonin gene-related peptide receptor antagonists for migraine therapy.

Major players in the calcitonin gene-related peptide receptor antagonist market are Pfizer Inc., Merck & Co. Inc. , AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim Pharma GmbH & Co. KG, Sosei Group Corporation, Teva Pharmaceutical Industries Ltd., UCB S.A., Alder BioPharmaceuticals, Inc. , H. Lundbeck A/S, Otsuka Pharmaceutical Co. Ltd., Biosynth Carbosynth , Seurat Therapeutics Inc., Satsuma Pharmaceuticals Inc., Allergan plc , Brise Pharmaceutical (Shanghai) Co Ltd., Nuvie Biopharma Inc.

North America was the largest region in the calcitonin gene-related peptide receptor antagonist market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in calcitonin gene-related peptide receptor antagonist report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the calcitonin gene-related peptide receptor antagonist market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The calcitonin gene-related peptide receptor antagonist market consists of sales of atogepant, orally disintegrating CGRP receptor, and intranasal CGRP receptor antagonist sprays. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Calcitonin Gene-Related Peptide Receptor Antagonist Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on calcitonin gene-related peptide receptor antagonist market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for calcitonin gene-related peptide receptor antagonist ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The calcitonin gene-related peptide receptor antagonist market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Small Molecule Antagonists; Monoclonal Antibodies; Peptide-Based Antagonists
• 2) By Drug Type: Zavegepant; Ubrogepant; Olcegepant; Telcegepant; Rimegepant; Other Drug Types
• 3) By Application: Migraine Treatment; Pain Management; Cardiovascular Conditions; Bone Disorders
• 4) By End-Users: Hospitals; Clinics; Homecare Settings; Pharmaceutical Companies
• Subsegments:
• 1) By Small Molecule Antagonists: Oral Small Molecule Antagonists; Intranasal Small Molecule Antagonists; Injectable Small Molecule Antagonists
• 2) By Monoclonal Antibodies: Erenumab; Fremanezumab; Galcanezumab; Eptinezumab
• 3) By Peptide-Based Antagonists: CGRP Fragment-Based Antagonists; Peptidomimetic CGRP Antagonists
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc. ; AbbVie Inc.; Bristol-Myers Squibb Company; Novartis AG; Eli Lilly and Company; Amgen Inc.; Boehringer Ingelheim Pharma GmbH & Co. KG; Sosei Group Corporation; Teva Pharmaceutical Industries Ltd.; UCB S.A.; Alder BioPharmaceuticals, Inc. ; H. Lundbeck A/S; Otsuka Pharmaceutical Co. Ltd.; Biosynth Carbosynth ; Seurat Therapeutics Inc.; Satsuma Pharmaceuticals Inc.; Allergan plc ; Brise Pharmaceutical (Shanghai) Co Ltd.; Nuvie Biopharma Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Calcitonin Gene-Related Peptide Receptor Antagonist Market Characteristics

3. Calcitonin Gene-Related Peptide Receptor Antagonist Market Trends And Strategies

4. Calcitonin Gene-Related Peptide Receptor Antagonist Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Calcitonin Gene-Related Peptide Receptor Antagonist Growth Analysis And Strategic Analysis Framework

• 5.1. Global Calcitonin Gene-Related Peptide Receptor Antagonist PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Calcitonin Gene-Related Peptide Receptor Antagonist Market Growth Rate Analysis
• 5.4. Global Calcitonin Gene-Related Peptide Receptor Antagonist Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Calcitonin Gene-Related Peptide Receptor Antagonist Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Calcitonin Gene-Related Peptide Receptor Antagonist Total Addressable Market (TAM)

6. Calcitonin Gene-Related Peptide Receptor Antagonist Market Segmentation

• 6.1. Global Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Small Molecule Antagonists
• Monoclonal Antibodies
• Peptide-Based Antagonists
• 6.2. Global Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Zavegepant
• Ubrogepant
• Olcegepant
• Telcegepant
• Rimegepant
• Other Drug Types
• 6.3. Global Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Migraine Treatment
• Pain Management
• Cardiovascular Conditions
• Bone Disorders
• 6.4. Global Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Homecare Settings
• Pharmaceutical Companies
• 6.5. Global Calcitonin Gene-Related Peptide Receptor Antagonist Market, Sub-Segmentation Of Small Molecule Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Small Molecule Antagonists
• Intranasal Small Molecule Antagonists
• Injectable Small Molecule Antagonists
• 6.6. Global Calcitonin Gene-Related Peptide Receptor Antagonist Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Erenumab
• Fremanezumab
• Galcanezumab
• Eptinezumab
• 6.7. Global Calcitonin Gene-Related Peptide Receptor Antagonist Market, Sub-Segmentation Of Peptide-Based Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• CGRP Fragment-Based Antagonists
• Peptidomimetic CGRP Antagonists

7. Calcitonin Gene-Related Peptide Receptor Antagonist Market Regional And Country Analysis

• 7.1. Global Calcitonin Gene-Related Peptide Receptor Antagonist Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Calcitonin Gene-Related Peptide Receptor Antagonist Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Calcitonin Gene-Related Peptide Receptor Antagonist Market

• 8.1. Asia-Pacific Calcitonin Gene-Related Peptide Receptor Antagonist Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Calcitonin Gene-Related Peptide Receptor Antagonist Market

• 9.1. China Calcitonin Gene-Related Peptide Receptor Antagonist Market Overview
• 9.2. China Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Calcitonin Gene-Related Peptide Receptor Antagonist Market

• 10.1. India Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Calcitonin Gene-Related Peptide Receptor Antagonist Market

• 11.1. Japan Calcitonin Gene-Related Peptide Receptor Antagonist Market Overview
• 11.2. Japan Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Calcitonin Gene-Related Peptide Receptor Antagonist Market

• 12.1. Australia Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Calcitonin Gene-Related Peptide Receptor Antagonist Market

• 13.1. Indonesia Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Calcitonin Gene-Related Peptide Receptor Antagonist Market

• 14.1. South Korea Calcitonin Gene-Related Peptide Receptor Antagonist Market Overview
• 14.2. South Korea Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Calcitonin Gene-Related Peptide Receptor Antagonist Market

• 15.1. Western Europe Calcitonin Gene-Related Peptide Receptor Antagonist Market Overview
• 15.2. Western Europe Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Calcitonin Gene-Related Peptide Receptor Antagonist Market

• 16.1. UK Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Calcitonin Gene-Related Peptide Receptor Antagonist Market

• 17.1. Germany Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Calcitonin Gene-Related Peptide Receptor Antagonist Market

• 18.1. France Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Calcitonin Gene-Related Peptide Receptor Antagonist Market

• 19.1. Italy Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Calcitonin Gene-Related Peptide Receptor Antagonist Market

• 20.1. Spain Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Calcitonin Gene-Related Peptide Receptor Antagonist Market

• 21.1. Eastern Europe Calcitonin Gene-Related Peptide Receptor Antagonist Market Overview
• 21.2. Eastern Europe Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Calcitonin Gene-Related Peptide Receptor Antagonist Market

• 22.1. Russia Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Calcitonin Gene-Related Peptide Receptor Antagonist Market

• 23.1. North America Calcitonin Gene-Related Peptide Receptor Antagonist Market Overview
• 23.2. North America Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Calcitonin Gene-Related Peptide Receptor Antagonist Market

• 24.1. USA Calcitonin Gene-Related Peptide Receptor Antagonist Market Overview
• 24.2. USA Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Calcitonin Gene-Related Peptide Receptor Antagonist Market

• 25.1. Canada Calcitonin Gene-Related Peptide Receptor Antagonist Market Overview
• 25.2. Canada Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Calcitonin Gene-Related Peptide Receptor Antagonist Market

• 26.1. South America Calcitonin Gene-Related Peptide Receptor Antagonist Market Overview
• 26.2. South America Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Calcitonin Gene-Related Peptide Receptor Antagonist Market

• 27.1. Brazil Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Calcitonin Gene-Related Peptide Receptor Antagonist Market

• 28.1. Middle East Calcitonin Gene-Related Peptide Receptor Antagonist Market Overview
• 28.2. Middle East Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Calcitonin Gene-Related Peptide Receptor Antagonist Market

• 29.1. Africa Calcitonin Gene-Related Peptide Receptor Antagonist Market Overview
• 29.2. Africa Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Calcitonin Gene-Related Peptide Receptor Antagonist Market Competitive Landscape And Company Profiles

• 30.1. Calcitonin Gene-Related Peptide Receptor Antagonist Market Competitive Landscape
• 30.2. Calcitonin Gene-Related Peptide Receptor Antagonist Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Calcitonin Gene-Related Peptide Receptor Antagonist Market Other Major And Innovative Companies

• 31.1. Eli Lilly and Company
• 31.2. Amgen Inc.
• 31.3. Boehringer Ingelheim Pharma GmbH & Co. KG
• 31.4. Sosei Group Corporation
• 31.5. Teva Pharmaceutical Industries Ltd.
• 31.6. UCB S.A.
• 31.7. Alder BioPharmaceuticals, Inc.
• 31.8. H. Lundbeck A/S
• 31.9. Otsuka Pharmaceutical Co. Ltd.
• 31.10. Biosynth Carbosynth
• 31.11. Seurat Therapeutics Inc.
• 31.12. Satsuma Pharmaceuticals Inc.
• 31.13. Allergan plc
• 31.14. Brise Pharmaceutical (Shanghai) Co Ltd.
• 31.15. Nuvie Biopharma Inc.

32. Global Calcitonin Gene-Related Peptide Receptor Antagonist Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Calcitonin Gene-Related Peptide Receptor Antagonist Market

34. Recent Developments In The Calcitonin Gene-Related Peptide Receptor Antagonist Market

35. Calcitonin Gene-Related Peptide Receptor Antagonist Market High Potential Countries, Segments and Strategies

• 35.1 Calcitonin Gene-Related Peptide Receptor Antagonist Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Calcitonin Gene-Related Peptide Receptor Antagonist Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Calcitonin Gene-Related Peptide Receptor Antagonist Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer